The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer

被引:120
作者
Bishop, Jennifer L. [1 ]
Thaper, Daksh [1 ]
Zoubeidi, Amina [1 ]
机构
[1] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada
关键词
STAT3; androgen receptor; prostate cancer; castrate resistance; CSC; metastasis; ENDOTHELIAL GROWTH-FACTOR; SMALL-MOLECULE INHIBITOR; TRANSCRIPTION; 3; STAT3; NF-KAPPA-B; IL-6-INDUCED NEUROENDOCRINE DIFFERENTIATION; ANTI-INTERLEUKIN-6; MONOCLONAL-ANTIBODY; REGULATES ANDROGEN RECEPTOR; SELECTIVE JAK2 INHIBITOR; TUMOR-INITIATING CELLS; HUMAN MULTIPLE-MYELOMA;
D O I
10.3390/cancers6020829
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The signal transducer and activator of transcription (STAT)3 governs essential functions of epithelial and hematopoietic cells that are often dysregulated in cancer. While the role for STAT3 in promoting the progression of many solid and hematopoietic malignancies is well established, this review will focus on the importance of STAT3 in prostate cancer progression to the incurable metastatic castration-resistant prostate cancer (mCRPC). Indeed, STAT3 integrates different signaling pathways involved in the reactivation of androgen receptor pathway, stem like cells and the epithelial to mesenchymal transition that drive progression to mCRPC. As equally important, STAT3 regulates interactions between tumor cells and the microenvironment as well as immune cell activation. This makes it a major factor in facilitating prostate cancer escape from detection of the immune response, promoting an immunosuppressive environment that allows growth and metastasis. Based on the multifaceted nature of STAT3 signaling in the progression to mCRPC, the promise of STAT3 as a therapeutic target to prevent prostate cancer progression and the variety of STAT3 inhibitors used in cancer therapies is discussed.
引用
收藏
页码:829 / 859
页数:31
相关论文
共 221 条
[31]   Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system [J].
Culig Z. ;
Hoffmann J. ;
Erdel M. ;
Eder I.E. ;
Hobisch A. ;
Hittmair A. ;
Bartsch G. ;
Utermann G. ;
Schneider M.R. ;
Parczyk K. ;
Klocker H. .
British Journal of Cancer, 1999, 81 (2) :242-251
[32]   p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6 [J].
Debes, JD ;
Comuzzi, B ;
Schmidt, LJ ;
Dehm, SM ;
Culig, Z ;
Tindall, DJ .
CANCER RESEARCH, 2005, 65 (13) :5965-5973
[33]   Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis [J].
Diaz, Tania ;
Navarro, Alfons ;
Ferrer, Gerardo ;
Gel, Bernat ;
Gaya, Anna ;
Artells, Rosa ;
Bellosillo, Beatriz ;
Garcia-Garcia, Mar ;
Serrano, Sergi ;
Martinez, Antonio ;
Monzo, Mariano .
PLOS ONE, 2011, 6 (04)
[34]  
Díaz-Laviada I, 2010, FUTURE ONCOL, V6, P1545, DOI [10.2217/fon.10.117, 10.2217/FON.10.117]
[35]   A Selective, Orally Bioavailable 1,2,4-Triazolo[1;5-a]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779 [J].
Dugan, Benjamin J. ;
Gingrich, Diane E. ;
Mesaros, Eugen F. ;
Milkiewicz, Karen L. ;
Curry, Matthew A. ;
Zulli, Allison L. ;
Dobrzanski, Pawel ;
Serdikoff, Cynthia ;
Jan, Mahfuza ;
Angeles, Thelma S. ;
Albom, Mark S. ;
Mason, Jennifer L. ;
Aimone, Lisa D. ;
Meyer, Sheryl L. ;
Huang, Zeqi ;
Wells-Knecht, Kevin J. ;
Ator, Mark A. ;
Ruggeri, Bruce A. ;
Dorsey, Bruce D. .
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (11) :5243-5254
[36]   Cucurbitacin E-induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells [J].
Duncan, KLK ;
Duncan, MD ;
ALley, MC ;
Sausville, EA .
BIOCHEMICAL PHARMACOLOGY, 1996, 52 (10) :1553-1560
[37]   Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site [J].
Eisermann, Kurtis ;
Broderick, Carly J. ;
Bazarov, Anton ;
Moazam, Mustafa M. ;
Fraizer, Gail C. .
MOLECULAR CANCER, 2013, 12
[38]   Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells [J].
Faderl, Stefan ;
Ferrajoli, Alessandra ;
Harris, David ;
Van, Quin ;
Kantarjian, Hagop M. ;
Estrov, Zeev .
LEUKEMIA RESEARCH, 2007, 31 (01) :91-95
[39]   Infiltrating Macrophages Promote Prostate Tumorigenesis via Modulating Androgen Receptor-Mediated CCL4-STAT3 Signaling [J].
Fang, Lei-Ya ;
Izumi, Kouji ;
Lai, Kuo-Pao ;
Liang, Liang ;
Li, Lei ;
Miyamoto, Hiroshi ;
Lin, Wen-Jye ;
Chang, Chawnshang .
CANCER RESEARCH, 2013, 73 (18) :5633-5646
[40]   Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer [J].
Fizazi, K. ;
De Bono, J. S. ;
Flechon, A. ;
Heidenreich, A. ;
Voog, E. ;
Davis, N. B. ;
Qi, Ming ;
Bandekar, R. ;
Vermeulen, J. T. ;
Cornfeld, M. ;
Hudes, G. R. .
EUROPEAN JOURNAL OF CANCER, 2012, 48 (01) :85-93